Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia but does not add to prognostic utility of the revised IPSS

Reliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline has been associated with achieving response and survival adv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Zeidan, Amer M, Lee, Ju-Whei, Prebet, Thomas, Greenberg, Peter, Sun, Zhuoxin, Juckett, Mark, Smith, Mitchell R, Paietta, Elisabeth, Gabrilove, Janice, Erba, Harry P, Tallman, Martin S., Gore, Steven D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4299466/
https://ncbi.nlm.nih.gov/pubmed/24995683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados